Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kasamon, Yvette L., Jacene, Heather A., Gocke, Christopher D., Swinnen, Lode J., Gladstone, Douglas E., Perkins, Brandy, Link, Brian K., Popplewell, Leslie L., Habermann, Thomas M., Herman, Joseph M., Matsui, William H., Jones, Richard J., Ambinder, Richard F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3359734/
https://ncbi.nlm.nih.gov/pubmed/22343727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-01-402792
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados